Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Market movers: Tesla, Novo Nordisk, Redfin...

Checkpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries.

Under the agreement, Sun Pharma will acquire Checkpoint for $4.10 per share in cash, representing up to $355 million in upfront payments.

Read more

Redfin Corp (NASDAQ:RDFN) shares surged more than 70% after the fintech company annoucned it is being acquired by Rocket Companies Inc (NYSE:RKT) in a transaction valued at $1.75 billion.

In the all-stock transaction, Redfin will be acquired for $12.50 per share.

Read more

Tesla Inc (NASDAQ:TSLA) shares fell another 8.7% to about $240 on Monday morning amid continued investor concerns about a slowdown in vehicle global sales and CEO Elon Musk’s close ties to the Trump administration.

Analysts at UBS lowered their price target on Tesla to $225 from $259 citing concerns over delivery volumes, margin pressures, and softer demand.

Read more

Novo Nordisk (NYSE:NVO) shares moved lower after the Danish drugmaker unveiled the latest trial results for its weight loss drug CagriSema.

The Phase 3 trial, called Redefine 2, showed that CagriSema helped obese or overweight adults with type 2 diabetes reduce their weight by 15.7% after 68 weeks, compared to 3.1% with placebo.

Read more

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares climbed 5% in early trading after securing a major deal to expand its Xenon MRI technology into pharmaceutical research.

A top global pharmaceutical company has selected Polarean’s imaging services for a multi-centre clinical trial, which will evaluate an investigational lung treatment.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK